KURA Reports $2.1M Q4 Revenue, $667.2M Cash, Launches KOMZIFTI for AML, Phase 3 KOMET-017 Initiated, $180M Collaboration Payments Expected
Kura Oncology, Inc. · PHARMACEUTICAL PREPARATIONS · Now $9.03
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS